Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RA9C
|
|||
| Drug Name |
CCT301-38 (targeting ROR2)
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 1/2 | [1] | |
| Company |
Shanghai Sinobioway Sunterra Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR2 (ROR2) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.